Table 5. Outcomes of adults undergoing... | American Society of Hematology

Table 5.

Outcomes of adults undergoing URD BMT after conditioning with various myeloablative and reduced-intensity regimens

Source	Regimen	Median follow-up, y	GF, %	Fatal RROT, %	TRM, % 100 d/1 y	Disease recurrence, %	KM OS at 1 y AL/CML/MDS	KM DFS at 1 y AL/CML/MDS
Cornelissen et al⁴⁴ n = 127^*	> 1000 cGy/Cy†	2.0	13	30	45/52	18	40/—/—	40/—/—
Maris et al²⁵ n = 89	200 cGy ± Flu	1.1	21	8	11/16	51	47/61/29	47/21/25
Current study n = 110	550 cGy/Cy	2.3	7.7	2	18/30	37	69/45/31	60/30/25

Source	Regimen	Median follow-up, y	GF, %	Fatal RROT, %	TRM, % 100 d/1 y	Disease recurrence, %	KM OS at 1 y AL/CML/MDS	KM DFS at 1 y AL/CML/MDS
Cornelissen et al⁴⁴ n = 127^*	> 1000 cGy/Cy†	2.0	13	30	45/52	18	40/—/—	40/—/—
Maris et al²⁵ n = 89	200 cGy ± Flu	1.1	21	8	11/16	51	47/61/29	47/21/25
Current study n = 110	550 cGy/Cy	2.3	7.7	2	18/30	37	69/45/31	60/30/25

GF indicates graft failure; Cy, cyclophosphamide; Flu, fludarabine; AL, leukemia in CR; —, NA.

Included only adults with ALL in CR₁, CR₂, or relapse.

Regimes were Cy/TBI (67 patients), Cy/TBI + cytarabine (Ara-C) or etoposide (VP16) (34 patients), or other (26 patients).